JPWO2020157577A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020157577A5 JPWO2020157577A5 JP2021544351A JP2021544351A JPWO2020157577A5 JP WO2020157577 A5 JPWO2020157577 A5 JP WO2020157577A5 JP 2021544351 A JP2021544351 A JP 2021544351A JP 2021544351 A JP2021544351 A JP 2021544351A JP WO2020157577 A5 JPWO2020157577 A5 JP WO2020157577A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- biphenyl
- chloro
- amino
- diazaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 10
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 claims description 3
- 230000035533 AUC Effects 0.000 claims description 3
- 230000000977 initiatory Effects 0.000 claims description 3
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 claims description 3
- 230000002485 urinary Effects 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 210000004072 Lung Anatomy 0.000 claims description 2
- 229940076279 Serotonin Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 230000002685 pulmonary Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 30
- BGMBESSESNFHQD-UHFFFAOYSA-M [O-]C(=O)C1CC2(CN1)CCNCC2 Chemical compound [O-]C(=O)C1CC2(CN1)CCNCC2 BGMBESSESNFHQD-UHFFFAOYSA-M 0.000 claims 1
- 230000037348 biosynthesis Effects 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 125000006005 fluoroethoxy group Chemical group 0.000 claims 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798827P | 2019-01-30 | 2019-01-30 | |
| US62/798,827 | 2019-01-30 | ||
| PCT/IB2020/000074 WO2020157577A1 (en) | 2019-01-30 | 2020-01-30 | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022518944A JP2022518944A (ja) | 2022-03-17 |
| JPWO2020157577A5 true JPWO2020157577A5 (zh) | 2022-12-19 |
Family
ID=70285725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544351A Pending JP2022518944A (ja) | 2019-01-30 | 2020-01-30 | 肺動脈性肺高血圧症を治療するための投与レジメンおよび方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11607413B2 (zh) |
| EP (1) | EP3917531A1 (zh) |
| JP (1) | JP2022518944A (zh) |
| KR (1) | KR20210133953A (zh) |
| CN (1) | CN113557022A (zh) |
| AU (1) | AU2020213746A1 (zh) |
| CA (1) | CA3128327A1 (zh) |
| MX (1) | MX2021009055A (zh) |
| WO (1) | WO2020157577A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021005559A (es) * | 2018-11-14 | 2021-09-10 | Altavant Sciences Gmbh | Compuesto espirocíclico cristalino, forma de dosificación que lo contiene, procedimiento de uso en el tratamiento de una enfermedad y procedimiento de recristalización. |
| WO2020099926A1 (en) | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| US11607413B2 (en) | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| WO2023062595A1 (en) | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201070127A1 (ru) | 2007-07-11 | 2010-08-30 | Лексикон Фармасьютикалз , Инк. | Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| MX2021005559A (es) | 2018-11-14 | 2021-09-10 | Altavant Sciences Gmbh | Compuesto espirocíclico cristalino, forma de dosificación que lo contiene, procedimiento de uso en el tratamiento de una enfermedad y procedimiento de recristalización. |
| WO2020099926A1 (en) * | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| US20200188398A1 (en) | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating sarcoidosis-associated pulmonary hypertension |
| US20200188399A1 (en) | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating interstitial lung disease |
| US11607413B2 (en) | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) * | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-01-30 US US16/777,458 patent/US11607413B2/en active Active
- 2020-01-30 CA CA3128327A patent/CA3128327A1/en active Pending
- 2020-01-30 MX MX2021009055A patent/MX2021009055A/es unknown
- 2020-01-30 AU AU2020213746A patent/AU2020213746A1/en active Pending
- 2020-01-30 CN CN202080016400.5A patent/CN113557022A/zh active Pending
- 2020-01-30 WO PCT/IB2020/000074 patent/WO2020157577A1/en unknown
- 2020-01-30 KR KR1020217024232A patent/KR20210133953A/ko unknown
- 2020-01-30 EP EP20718760.0A patent/EP3917531A1/en not_active Withdrawn
- 2020-01-30 JP JP2021544351A patent/JP2022518944A/ja active Pending
-
2023
- 2023-01-25 US US18/159,494 patent/US20240041877A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9737540B2 (en) | Combination treatment of cancer | |
| US4634703A (en) | Method for alleviation of panic disorders | |
| KR101900520B1 (ko) | 복합 조성물 | |
| CZ284928B6 (cs) | Použití riluzolu pro výrobu léčiva určeného k léčení Parkinsonovy choroby a Parkinsonových syndromů | |
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| JPWO2020157577A5 (zh) | ||
| EP3937928A1 (en) | Capsid assembly modulator solid formulation | |
| EP3954374A1 (en) | Pharmaceutical combination of pimozide and methotrexate and use thereof | |
| JP2008539265A5 (zh) | ||
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
| WO2022122040A1 (zh) | 白果内酯或银杏内酯组合物在制备镇静药物中的应用 | |
| JP2012508232A (ja) | マラリアの治療のためのハイポエストキシド誘導体 | |
| US20240216333A1 (en) | Treatment of glioblastoma | |
| TW536400B (en) | Pharmaceutical composition for the treatment of immunodeficiency disease which cause by HIV infection | |
| JPWO2020188352A5 (zh) | ||
| AU2005224154A1 (en) | Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition | |
| WO2016093781A1 (en) | Concentrated parenteral methotraxate formulations | |
| US20210220371A1 (en) | Method for smoking cessation | |
| CN112007024A (zh) | 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途 | |
| JPS5920221A (ja) | レイノ−症状の改善・治療剤 | |
| CN114869908A (zh) | 一种辅助促进睡眠的药物制剂及其制备方法 | |
| JP2022177119A5 (zh) |